# Rui-Hua Xu

Source: https://onco.cc/people/xu-rui-hua/  
OnCo record `xu-rui-hua` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leads China's largest cancer centre and has run the Chinese phase 3 trials that brought PD-1 antibodies into GI cancer.

## Summary

Rui-Hua Xu is President of Sun Yat-sen University Cancer Center in Guangzhou, China's largest cancer centre, and Professor of Medical Oncology. A gastrointestinal oncologist, he has run the Chinese phase 3 trials that brought PD-1 antibodies into gastrointestinal cancer, including JUPITER-06 with toripalimab in oesophageal cancer and studies of camrelizumab in ESCORT-1st, fruquintinib and anti-EGFR therapy, establishing immunotherapy and targeted therapy for Chinese patients. His publications include the JUPITER-06 trial of toripalimab plus paclitaxel and cisplatin as first-line treatment for advanced oesophageal squamous cell carcinoma. His interests span colorectal, oesophageal and gastric cancer and immunotherapy.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: President, Sun Yat-sen University Cancer Center; Professor of Medical Oncology
- Specialisms: Gastrointestinal oncology; Colorectal cancer; Oesophageal and gastric cancer; Immunotherapy

## Sources

- Sun Yat-sen University Cancer Center: https://www.sysucc.org.cn
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Xu%20RH%5BAuthor%5D%20Sun%20Yat-sen%20gastrointestinal

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Camrelizumab](https://onco.cc/drugs/camrelizumab/), [Fruquintinib](https://onco.cc/drugs/fruquintinib/), [Toripalimab](https://onco.cc/drugs/toripalimab/)
- institutions: [Chinese Society of Clinical Oncology](https://onco.cc/institutions/csco/), [Sun Yat-sen University Cancer Center](https://onco.cc/institutions/sysucc/)
- trials: [ESCORT-1st](https://onco.cc/trials/escort-1st/), [JUPITER-06](https://onco.cc/trials/jupiter-06/)
- journals: [Cancer Cell](https://onco.cc/journals/cancer-cell/)
- key papers: [SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer](https://onco.cc/key-papers/paper-spotlight-lancet-2023/)

---
JSON: https://onco.cc/api/v1/entities/xu-rui-hua.json